Article
Patient selection for anti-PD-1/PD-L1 therapy in advanced non-small-cell lung cancer: implications for clinical practice.
Future oncology (London, England) - 1 Oct 2018
Califano Raffaele, Lal Rohit, Lewanski Conrad, Nicolson Marianne C, Ottensmeier Christian H, Popat Sanjay, Hodgson Matthew, Postmus Pieter E
Abstract excerpt
Immune checkpoint inhibitors targeting PD-1 or PD-L1 represent a standard treatment option for patients with advanced non-small-cell lung cancer. However, a substantial proportion of patients will not benefit from these treatments, and robust biomarkers are required to help clinicians select patients who are most likely to benefit. Here, we discuss the available evidence on the utility of clinical characteristics...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.